Litigation Details for BRISTOL-MYERS SQUIBB COMPANY v. DR. REDDYS LABORATORIES, LTD. (D.N.J. 2019)
✉ Email this page to a colleague
BRISTOL-MYERS SQUIBB COMPANY v. DR. REDDYS LABORATORIES, LTD. (D.N.J. 2019)
| Docket | ⤷ Try a Trial | Date Filed | 2019-10-03 |
| Court | District Court, D. New Jersey | Date Terminated | 2021-07-15 |
| Cause | 35:271 Patent Infringement | Assigned To | Michael Andre Shipp |
| Jury Demand | None | Referred To | Tonianne J. Bongiovanni |
| Parties | BRISTOL-MYERS SQUIBB COMPANY | ||
| Patents | 7,491,725; 8,680,103 | ||
| Attorneys | WILLIAM T. WALSH , JR | ||
| Firms | Lerner, David, Littenberg, Krumholz & Mentlik, LLP | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in BRISTOL-MYERS SQUIBB COMPANY v. DR. REDDYS LABORATORIES, LTD.
The small molecule drug covered by the patents cited in this case is ⤷ Try a Trial .
Details for BRISTOL-MYERS SQUIBB COMPANY v. DR. REDDYS LABORATORIES, LTD. (D.N.J. 2019)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2021-05-06 | 104 | Memorandum | No. 7,491,725 ("725 Patent”), U.S. Patent No. 8,680,103 (“’103 Patent”), and U.S. Patent No. 8,…8,242,270 (“’270 Patent”) (collectively, “Patents”). The parties seek construction of two terms found …construction. Il. LOCAL PATENT RULES This Court has established its own Local Patent Rules which serve “[…precisely what the Local Patent Rules were designed to prevent. “The Local Patent Rules are designed so …preliminary claim constructions for terms of U.S. Patent Case 3:19-cv-18686-MAS-TJB Document 104 Filed 05 | External link to document |
| 2020-02-10 | 37 | Amended Complaint | and legally issued United States Patent No. 7,491,725 (“the ’725 patent”) entitled “Process for preparing…prior to the expiration of United States Patent Nos. 7,491,725, 8,680,103, and/or 8,242,270. … U.S. PATENT NO. 7,491,725 On February 17, 2009, the…is an action for patent infringement arising under the Food and Drug Laws and Patent Laws of the United… correct copy of the ’725 patent is attached as Exhibit 1. The ’725 patent is assigned to BMS. | External link to document |
| 2020-07-30 | 58 | claims of BMS’ U.S. Patent Nos. 7,491,725 (“the ’725 patent”), 8,242,270 (“the ’270 patent”), and 8,680,103… of the ’725 patent, claim 3 of the ’103 patent, and claims 7 and 9 of the ’270 patent. I…and ’103 patents relate to crystalline forms of dasatinib. The art disclosed in these patents relates…’725 and ’103 patents lists each of the values recited in claim 3 of the ’725 patent, and claim 3 of…’725 Patent, 43:48-49; ’103 Patent, 45:16-17. Example 8 indicates that “[o]ne of ordinary skill in | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
